13 May 2019
Vedanta Biosciences Closes Extended $45.5 Million Series C Financing
Vedanta Biosciences, a clinical-stage company developing a new category of therapies for immune-mediated diseases based on rationally-defined consortia of human...
Life Sciences
8 May 2019
Vedanta Biosciences Key Microbiome Patent Upheld in European Opposition Proceedings
Upheld patent EP2575835 covers therapeutic compositions of clostridial bacterial species derived from the human microbiome. Decision further solidifies Vedanta’s leading IP...
29 April 2019
Mdoloris Announces CE Marking of the Analgesia Nociception Index (ANI®) Module for the Masimo Root® Patient Monitoring and Connectivity Hub
ANI provides an objective, noninvasive, and continuous way to automatically monitor the pain level of patients. The Root platform, with its open architecture and built-in...
22 March 2019
Enterome announces research collaboration with renowned US Cancer Institute focused on new microbiome-derived cancer immunotherapy
New collaboration to evaluate the potential of bacterial antigens that mimic tumor antigens and neoantigens ("onco-mimics") to drive immune responses.
11 March 2019
Axial Biotherapeutics Raises $25 Million in Series B Financing
Funds will be used to advance Axial’s gut-targeted programs in Parkinson’s Disease and Autism Spectrum Disorder. Seventure Partners commits new funding from...
5 March 2019
Health for Life Capital II™, World Leading Microbiome-focused Fund Announces its First Close
Health for Life Capital II™ to focus on the microbiome, and health, nutrition and digital/connected health sectors.
1 March 2019
Seventure Partners Life Sciences Corporate Update September 2018 – February 2019
Seventure Partners, one of Europe’s leaders in financing innovation and a world-leader in the venture investment in the microbiome sector, is pleased to provide an update on...
21 February 2019
BiomX raises $32M series B to bring first two therapies to clinic
Phage therapy company BiomX Ltd. (Ness Ziona, Israel) raised a $32 million series B round on Wednesday, 20th February, that will take its lead candidate, acne therapy BX001,...
20 February 2019
Seventure Keeps up Pace of Its International Microbiome Investments, Closing Four Deals Spanning Seed to Series C
Seventure Keeps up Pace of Its International Microbiome Investments, Closing Four Deals Spanning Seed to Series C
19 February 2019
Vedanta Biosciences Publishes Seminal Research in Leading Scientific Journal for its Immuno-oncology Candidate, VE800
Vedanta Bioscience, a clinical-stage company developing a new category of therapies for immune-mediated diseases based on rationally-defined consortia of human...